Skip to main content
Premium Trial:

Request an Annual Quote

Preliminary One-patient Data Suggest Benitec HCV Drug Safe, Well Tolerated

Premium

NEW YORK (GenomeWeb) – Benitec Biopharma said this week that laboratory data on the first patient dosed in its Phase I/IIa trial its expressed RNAi treatment for hepatitis C indicate that the drug is safe and well tolerated.

TT-034 is designed to express shRNAs targeting three regions of the HCV genome. The clinical study, which is set to enroll up to 14 HCV patients, began in June.

Benitec also said that a second patient has been identified for dosing in the study, just weeks after disclosing that two potential trial participants had failed to meet its inclusion criteria due to fluctuations in viral load and liver enzymes that were outside of acceptable ranges.

According to the firm, the newly identified patient is currently within the study protocol's clinical parameters and that they will receive TT-034 upon the successful completion of a 28-day screening process.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.